SCHEMBL7009380

SCHEMBL7009380

O=c1[nH]c(=S)n(Cc2cccnc2)cc1Cc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 3/20 0.48
MAPK10 P53779 1/20 0.48
PLA2G7 Q13093 6/20 0.47
MAPK1 P28482 2/20 0.44
UPP1 Q16831 1/20 0.44
KDM4E B2RXH2 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
KMT2A Q03164 3/20 0.42
MEN1 O00255 2/20 0.42
OPRM1 P35372 1/20 0.42
OPRD1 P41143 1/20 0.42
POLB P06746 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
ALDH1A1 P00352 3/20 0.41
CHRM1 P11229 1/20 0.41
GAA P10253 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7013517 0.92 PKM (0.45) PKMMAPK10PLA2G7MAPK1KDM4E
SCHEMBL7012551 0.88 PLA2G7 (0.47) PLA2G7UPP1KDM4ECYP2C9ALDH1A1
SCHEMBL7007953 0.87 UPP1 (0.51) UPP1KMT2AMEN1CYP2C9ALDH1A1
SCHEMBL7013431 0.86 PLA2G7 (0.54) PLA2G7UPP1ALDH1A1
SCHEMBL7012513 0.84 PLA2G7 (0.44) PKMMAPK10PLA2G7MAPK1KDM4E
SCHEMBL7012155 0.81 UPP1 (0.44) PKMPLA2G7UPP1KDM4EKMT2A
SCHEMBL7564706 0.80 PLA2G7 (0.42) PKMMAPK10PLA2G7UPP1GAA
SCHEMBL7007609 0.80 PLA2G7 (0.46) PKMMAPK10PLA2G7
SCHEMBL7005556 0.79 PLA2G7 (0.43) PKMPLA2G7KDM4EALDH1A1HSD17B10
SCHEMBL7010539 0.77 PLA2G7 (0.55) PLA2G7UPP1KDM4EKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1028955-B1 PYRIMIDINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SMITHKLINE BEECHAM PLC (GB) 2003-07-16 EP disclosed
US-20020120139-A1 Pyrimidinone compounds and pharmaceutical compositions containing them HICKEY DEIRDRE MARY BERNADETTE (GB) 2002-08-29 US disclosed
US-6417192-B1 DRUGS WITH PYRIMIDONE COMPOUNDS INHIBITORS OF THE ENZYME LDL PLA.SUB.2 AND THEREFORE OF USE IN TREATING ATHEROSCLEROSIS. SMITHKLINE BEECHAM P.L.C. (GB) 2002-07-09 US disclosed
EP-1028955-A1 PYRIMIDINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SmithKline Beecham p.l.c. (GB) 2000-08-23 EP disclosed
WO-1999024420-A1 PYRIMIDINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SMITHKLINE BEECHAM PLC (GB) 1999-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020120139-A1 Pyrimidinone compounds and pharmaceutical compositions containing them PLA2G7, PLA2G1B, PLA2G4C PKM 1180/4885MAPK10 4038/4885PLA2G7 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.